Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

Deok Beom Jung, Miyong Yun, Eun Ok Kim, Jaekwang Kim, Bonglee Kim, Ji Hoon Jung, Enfeng Wang, Debabrata Mukhopadhyay, Edward Hammond, Keith Dredge, Viji Shridhar, Sung Hoon Kim

Research output: Contribution to journalComment/debate

Abstract

The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

Original languageEnglish (US)
Number of pages1
JournalOncotarget
Volume10
Issue number54
DOIs
StatePublished - Sep 1 2019

Fingerprint

gemcitabine
Catenins
Heparitin Sulfate
Carcinogenesis
Control Groups
Cyclin D1
Proliferating Cell Nuclear Antigen

ASJC Scopus subject areas

  • Oncology

Cite this

Correction : The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214). / Jung, Deok Beom; Yun, Miyong; Kim, Eun Ok; Kim, Jaekwang; Kim, Bonglee; Jung, Ji Hoon; Wang, Enfeng; Mukhopadhyay, Debabrata; Hammond, Edward; Dredge, Keith; Shridhar, Viji; Kim, Sung Hoon.

In: Oncotarget, Vol. 10, No. 54, 01.09.2019.

Research output: Contribution to journalComment/debate

@article{f06e89ffbde84210a26c047596a0b739,
title = "Correction: The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)",
abstract = "The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)",
author = "Jung, {Deok Beom} and Miyong Yun and Kim, {Eun Ok} and Jaekwang Kim and Bonglee Kim and Jung, {Ji Hoon} and Enfeng Wang and Debabrata Mukhopadhyay and Edward Hammond and Keith Dredge and Viji Shridhar and Kim, {Sung Hoon}",
year = "2019",
month = "9",
day = "1",
doi = "10.18632/oncotarget.27216",
language = "English (US)",
volume = "10",
journal = "Oncotarget",
issn = "1949-2553",
publisher = "Impact Journals",
number = "54",

}

TY - JOUR

T1 - Correction

T2 - The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine (Oncotarget (2015) 6 (4992–5004) DOI: 10.18632/oncotarget.3214)

AU - Jung, Deok Beom

AU - Yun, Miyong

AU - Kim, Eun Ok

AU - Kim, Jaekwang

AU - Kim, Bonglee

AU - Jung, Ji Hoon

AU - Wang, Enfeng

AU - Mukhopadhyay, Debabrata

AU - Hammond, Edward

AU - Dredge, Keith

AU - Shridhar, Viji

AU - Kim, Sung Hoon

PY - 2019/9/1

Y1 - 2019/9/1

N2 - The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

AB - The IHC pictures of ‘Control #1 group’ and ‘PG545 #2 group’ have been removed from Figure 6. In addition, the ‘Cyclin D1 in Control 1 group’ is mistakenly similar to the IHC picture of ‘PCNA in Gem group’ already presented in Figure 5F. The corrected Figure 6 is shown below. The authors declare that these corrections do not change the results or conclusions of this paper. (Figure presented.)

UR - http://www.scopus.com/inward/record.url?scp=85072710058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072710058&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.27216

DO - 10.18632/oncotarget.27216

M3 - Comment/debate

AN - SCOPUS:85072710058

VL - 10

JO - Oncotarget

JF - Oncotarget

SN - 1949-2553

IS - 54

ER -